Home LiteratureArticle Details
PMID: 2055485 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S. Review

Modulation of HIV-enhancer activity by heterologous agents: a minireview.

Gene ·Vol. 101 ·No. 2 ·1991-05-30 ·Pages 165-70

Chinnadurai G

Abstract

The enhancer region of the human immunodeficiency virus (HIV) long terminal repeat (LTR) contains two 10-bp (5'-GGGACTTTCC) repeats (core enhancers) which constitute the binding sites for the ubiquitous inducible cellular transcription factor, NF-kappa B. The NF-kappa B motifs of the LTR play a central role in transcriptional activation of the LTR by several heterologous viral proteins and various external chemical and physical stimuli. Activation of the HIV enhancer by these agents may lead to the onset of HIV gene expression resulting in active viral replication. Viral genes and chemical agents, which interfere with the activity of the enhancers may be useful in inhibiting HIV gene expression, thereby suppressing HIV replication.

MeSH Terms
Base Sequence Gene Expression Regulation, Viral HIV/genetics,physiology HIV Enhancer/physiology HIV Long Terminal Repeat/genetics,physiology Molecular Sequence Data NF-kappa B/physiology Transcription, Genetic Transcriptional Activation/physiology Virus Replication
Chemicals
NF-kappa B
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Chinnadurai G
Institute for Molecular Virology, St. Louis University Medical Center, MO 63110.
Article Info
Journal
Gene
Abbr.
Gene
ISSN
0378-1119
Published
1991-05-30
Pages
165-70
Language
English
Region
Netherlands
NLM ID
7706761
Subset
IM
Grants
NIAID NIH HHS · AI-29200 · United States
NIAID NIH HHS · AI-29541 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com